Sidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops next-generation bispecific ADCs for cancer treatment
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications
Pitching Goldman Sachs Alternatives Life Sciences? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room